{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:14:39Z","timestamp":1789038879852,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013398","name":"Sykehuset Innlandet HF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>The safety of varying plasma donation frequencies remains unclear. This non\u2010inferiority randomized controlled trial investigated the effect of plasma donation frequency on total serum protein (TSP), immunoglobulin G (IgG) concentrations, additional biomarkers, adverse events (AEs) and psychological distress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this trial, 120 male donors were randomized into three groups: high\u2010frequency plasma donors (HFPDs, three times every 2\u2009weeks), regular\u2010frequency plasma donors (RFPDs, once every 2\u2009weeks) and a control group (whole blood donation every 3\u2009months). Blood samples were collected biweekly from baseline until the last donation in Week 16 and 4\u2009weeks after the last donation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HFPDs completed median (range) 21.5 (1\u201324), RFPDs 8 (1\u20138) and controls 2 (1\u20132) donations. HFPDs had lower concentrations of TSP and IgG compared to controls, with a mean difference (95% confidence interval [CI]) of \u22125.5\u2009g\/L (\u22127.4, \u22123.6) and \u22122.8\u2009g\/L (\u22123.8, \u22121.8), respectively. Within\u2010group analysis revealed significant reductions, which increased with the frequency of donations, in TSP, IgG, IgG subclasses, immunoglobulin M (IgM), immunoglobulin A (IgA), ferritin and haemoglobin. Many of the biomarkers required more than 4\u2009weeks to return to baseline levels. Only mild AEs were reported, and plasma donation frequency had no effect on psychological distress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High\u2010 and regular\u2010frequency plasmapheresis substantially reduces concentrations of TSP, IgG and other biomarkers, with greater reductions at higher donation frequencies. Further research is needed to assess the long\u2010term health implications of frequent plasma donation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.70105","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:28:57Z","timestamp":1756427337000},"page":"1205-1215","source":"Crossref","is-referenced-by-count":5,"title":["The effect of plasma donation frequency on total serum protein, immunoglobulin G and donor safety: A non\u2010inferiority randomized controlled trial"],"prefix":"10.1111","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9603-3808","authenticated-orcid":false,"given":"Morten","family":"Haugen","sequence":"first","affiliation":[{"name":"Innlandet Hospital Trust  Brumunddal Norway"},{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Sofie Haug","family":"Nissen\u2010Meyer","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"},{"name":"Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor A.","family":"Strand","sequence":"additional","affiliation":[{"name":"Innlandet Hospital Trust  Brumunddal Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2039-4986","authenticated-orcid":false,"given":"Karin","family":"Magnussen","sequence":"additional","affiliation":[{"name":"Innlandet Hospital Trust  Brumunddal Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528959"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2020.12.005"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000696"},{"key":"e_1_2_9_5_1","unstructured":"Marketing Research Bureau.Data & Analysis of Immunoglobulin Supply and Plasma Requirements in Europe 2010\u20132021. Available from:https:\/\/marketingresearchbureau.com\/the-worldwide-plasma-proteins-market-2021\/. Last accessed 23 May 2025."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2021.09.004"},{"key":"e_1_2_9_7_1","unstructured":"Council of the European Union.Council adopts new rules on substances of human origin. Available from:https:\/\/www.consilium.europa.eu\/en\/press\/press-releases\/2024\/05\/27\/council-adopts-new-rules-on-substances-of-human-origin\/. Last accessed 30 Jun 2025."},{"key":"e_1_2_9_8_1","unstructured":"European Blood Alliance.Blood is a gift: EBA's new position on voluntary unpaid donations. Available from:https:\/\/europeanbloodalliance.eu\/resources\/blood\u2010is\u2010a\u2010gift\u2010ebas\u2010new\u2010position\u2010on\u2010voluntary\u2010unpaid\u2010donations\/. Last accessed 30 Jun 2025."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17369"},{"key":"e_1_2_9_10_1","unstructured":"US Food and Drugs Administration.Guide to Inspections of Source Plasma Establishments \u2013 Section 2. Available from:https:\/\/www.fda.gov\/inspections\u2010compliance\u2010enforcement\u2010and\u2010criminal\u2010investigations\/inspection\u2010guides\/section\u20102. Last accessed 23 May 2025."},{"key":"e_1_2_9_11_1","unstructured":"Council of Europe.Guide to the preparation use and quality assurance of blood components 20th Edition.2020. European Directorate for the Quality of Medicines & HealthCare (EDQM)."},{"key":"e_1_2_9_12_1","unstructured":"Council of Europe.Guide to the preparation use and quality assurance of blood components 21st Edition.2023. European Directorate for the Quality of Medicines & HealthCare (EDQM)."},{"key":"e_1_2_9_13_1","unstructured":"Council of Europe.Guide to the preparation use and quality assurance of blood components 22nd Edition.2025. European Directorate for the Quality of Medicines & HealthCare (EDQM)."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2024.150851"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13512"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13544"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00794.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01345.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.1993.tb00105.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13569"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08035-7"},{"key":"e_1_2_9_22_1","unstructured":"Helsedirektoratet.Veileder for transfusjonstjenesten i Norge.2017. Available from:https:\/\/www.helsedirektoratet.no\/veiledere\/transfusjonstjenesten\u2010i\u2010norge\u2010utgave\u201073\/Transfusjonstjenesten%20i%20Norge%20utgave%207.3%20\u2013%20Veileder.pdf\/_\/attachment\/inline\/6222d24e\u2010ebdc\u20104588\u2010a51f\u2010735cc17f58c6:ddb6d627e05b9f68918723bf59407db19602a601\/Transfusjonstjenesten%20i%20Norge%20utgave%207.3%20\u2013%20Veileder.pdf. Last accessed 22 Aug 2025."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08411.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12323"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15830"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/08039480310000932"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2021.100096"},{"key":"e_1_2_9_28_1","unstructured":"Sealed Envelope Ltd.Power calculator for continuous outcome equivalence trial. Available from:https:\/\/www.sealedenvelope.com\/power\/continuous-equivalence\/. Last accessed 23 May 2025"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-106"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.87802"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05364-9"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000230580"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104712"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2014.09.009"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17190"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.83221"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03055.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13771"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:18:37Z","timestamp":1765412317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/vox.70105"],"URL":"https:\/\/doi.org\/10.1111\/vox.70105","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}